Literature DB >> 28806117

Postdiagnosis Statin Use and Mortality in Danish Patients With Prostate Cancer.

Signe Benzon Larsen1, Christian Dehlendorff1, Charlotte Skriver1, Susanne Oksbjerg Dalton1, Christina Gade Jespersen1, Michael Borre1, Klaus Brasso1, Mette Nørgaard1, Christoffer Johansen1, Henrik Toft Sørensen1, Jesper Hallas1, Søren Friis1.   

Abstract

Purpose Increasing evidence indicates that statin use may reduce mortality from prostate cancer. In this work, we examined whether postdiagnosis statin use was associated with reduced cancer-specific mortality or all-cause mortality among patients with prostate cancer in Denmark. Material and Methods From nationwide Danish registries, we identified all patients with incident prostate adenocarcinoma from 1998 to 2011 and retrieved data on tumor and patient characteristics, drug use, and primary treatment. We defined postdiagnosis use (two or more prescriptions) of statins as a time-varying covariate with 1-year lag. Cox proportional hazards regression models used to compute hazard ratios (HRs) for prostate cancer-specific mortality and all-cause mortality through 2013 associated with postdiagnosis statin use. In secondary and sensitivity analyses, we assessed statin use within exposure periods of 1 year or 5 years after prostate cancer diagnosis and evaluated the influence of prediagnosis statin use. Results Among 31,790 patients, 7,365 died of prostate cancer and 11,811 died from other causes during a median follow-up of 2.8 years (interquartile range, 1.3 to 5.1 years) from 1 year after diagnosis. Postdiagnosis statin use was associated with adjusted HRs of 0.83 (95% CI, 0.77 to 0.89) for prostate cancer mortality and 0.81 (95% CI, 0.76 to 0.85) for all-cause mortality. Similar results were observed in 1-year and 5-year sensitivity analyses. No substantial effect measure modification was found with estimated dose or type of statin, clinical stage, Gleason score, or with prediagnosis statin use; however, patients who were diagnosed early in the study period or who underwent radical prostatectomy or endocrine therapy exhibited slightly lower HRs for prostate cancer mortality with postdiagnosis statin use than did those in the overall analyses. Conclusion Postdiagnosis statin use was associated with reduced mortality from prostate cancer; however, it remains to be established whether this association is causal.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28806117     DOI: 10.1200/JCO.2016.71.8981

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  27 in total

1.  Associations among statins, preventive care, and prostate cancer mortality.

Authors:  Abhishek Kumar; Paul Riviere; Elaine Luterstein; Vinit Nalawade; Lucas Vitzthum; Reith R Sarkar; Alex K Bryant; John P Einck; Arno J Mundt; James D Murphy; Brent S Rose
Journal:  Prostate Cancer Prostatic Dis       Date:  2020-02-06       Impact factor: 5.554

2.  Prostate cancer: Postdiagnosis statin use reduces mortality.

Authors:  Clemens Thoma
Journal:  Nat Rev Urol       Date:  2017-08-31       Impact factor: 14.432

3.  The impact of statins in combination with androgen deprivation therapyin patients with advanced prostate cancer: A large observational study.

Authors:  India Anderson-Carter; Natasza Posielski; Jinn-Ing Liou; Tariq A Khemees; Tracy M Downs; E Jason Abel; David F Jarrard; Kyle A Richards
Journal:  Urol Oncol       Date:  2018-12-07       Impact factor: 3.498

4.  Upregulation of Scavenger Receptor B1 Is Required for Steroidogenic and Nonsteroidogenic Cholesterol Metabolism in Prostate Cancer.

Authors:  Jacob A Gordon; Jake W Noble; Ankur Midha; Fatemeh Derakhshan; Gang Wang; Hans H Adomat; Emma S Tomlinson Guns; Yen-Yi Lin; Shancheng Ren; Collin C Collins; Peter S Nelson; Colm Morrissey; Kishor M Wasan; Michael E Cox
Journal:  Cancer Res       Date:  2019-05-07       Impact factor: 12.701

5.  Statins and Gliomas: A Systematic Review of the Preclinical Studies and Meta-Analysis of the Clinical Literature.

Authors:  Luis F Rendon; Ishaan A Tewarie; David J Cote; Aaron Gabriel; Timothy R Smith; Marike L D Broekman; Rania A Mekary
Journal:  Drugs       Date:  2022-02-05       Impact factor: 9.546

6.  In search of the optimal setting for statin trials in prostate cancer: the power of population-based studies.

Authors:  Emma H Allott; Emma L Craig; Konrad H Stopsack
Journal:  Prostate Cancer Prostatic Dis       Date:  2021-03-29       Impact factor: 5.455

7.  Association of Cardiovascular Risk Factors With Cardiac Events and Survival Outcomes Among Patients With Breast Cancer Enrolled in SWOG Clinical Trials.

Authors:  Dawn L Hershman; Cathee Till; Sherry Shen; Jason D Wright; Scott D Ramsey; William E Barlow; Joseph M Unger
Journal:  J Clin Oncol       Date:  2018-03-27       Impact factor: 44.544

8.  Regression of Periocular Basal Cell Carcinoma: A Report of Four Cases with Clinicopathologic Correlation.

Authors:  Martina C Herwig-Carl; Karin U Loeffler
Journal:  Ocul Oncol Pathol       Date:  2019-08-28

9.  Statins and Prostate Cancer: Bias, Precision Medicine, or Population Health?

Authors:  Konrad H Stopsack
Journal:  Eur Urol       Date:  2021-02-04       Impact factor: 24.267

10.  Prostate cancer prognosis after initiation of androgen deprivation therapy among statin users. A population-based cohort study.

Authors:  A Auvinen; T J Murtola; A I Peltomaa; P Raittinen; K Talala; K Taari; T L J Tammela
Journal:  Prostate Cancer Prostatic Dis       Date:  2021-03-31       Impact factor: 5.554

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.